We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Qiagen to Increase Safety of Blood Donations in Brazil

By LabMedica International staff writers
Posted on 09 Jun 2009
Qiagen (Frankfurt, Germany) has entered into an agreement to supply molecular sample and assay technologies for a new national, polymerase chain reaction (PCR)-based blood screening program for human immunodeficiency virus (HIV) and Hepatitis C (HCV) in Brazil. More...


The company will provide Bio-Manguinhos (Rio de Janeiro, Brazil), the main provider of vaccines and diagnostics to the Brazilian Ministry of Health, with molecular testing solutions, sample and assay technologies, instrumentation, operational know-how, and training. The agreement will run for five years and contains options for subsequent extensions.

Qiagen's extraction and testing components will be included in the screening kits and sold in a format featuring Bio-Manguinhos's name and branding. The kits will run on a high-throughput multiplex PCR platform, which allows processing of large numbers of samples and detecting multiple pathogens in a single run. The highly automated platform, which includes an advanced control system based on biosafe viruses developed by Bio-Manguinhos, been validated in the field.

Brazil's new national screening program is scheduled to start in 2010. Every year, five million blood donations are performed in Brazil (population--190 million), of which 70% are conducted by public blood banks. Approximately 0.1% and 0.3% of these donations are tested positive for HIV and HCV, respectively, using older, less sensitive serological methods. It is believed that the real percent of positives could be significantly higher.

Peer M. Schatz, CEO of Qiagen said, "We are proud to team up with the Brazilian authorities in a combined effort to significantly reduce the number of blood-borne transmissions of HIV and HCV and the resulting disease burden."

Bio-Manguinhos is one of the official laboratories of the Brazilian Ministry of Health. The unit supports disease prevention policies, epidemiologic programs, sanitation, and surveillance in the immunobiologic area.

Qiagen is a global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biologic samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible.

Related Links:

Qiagen
Bio-Manguinhos
Ministry of Health, Brazil



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.